Publications by authors named "J Adjemian"

Background: Because COVID-19 case data do not capture most SARS-CoV-2 infections, the actual risk of severe disease and death per infection is unknown. Integrating sociodemographic data into analysis can show consequential health disparities.

Methods: Data were merged from September 2020 to November 2021 from 6 national surveillance systems in matched geographic areas and analyzed to estimate numbers of COVID-19-associated cases, emergency department visits, and deaths per 100 000 infections.

View Article and Find Full Text PDF
Article Synopsis
  • Emergency department (ED) visit volumes were significantly affected by the COVID-19 pandemic, with a 32% drop in visits during Q2 2020, followed by a rebound to 2019 levels by Q2 2021.
  • The study analyzed ED visit trends by race, ethnicity, and age from December 30, 2018, to April 2, 2022, using data from the National Syndromic Surveillance Program, highlighting variations in visits over time and across demographic groups.
  • While ED visits returned to near pre-pandemic levels for adults, children showed a slower recovery, with visits remaining below baseline levels until Q3 2021 and then dropping again by Q4 2021.
View Article and Find Full Text PDF
Article Synopsis
  • National studies indicate that COVID-19 vaccination coverage positively affects health outcomes in adults, but its effects on children are less clear.
  • An analysis of children aged 5-17 demonstrated that higher pediatric vaccination coverage relates to significantly lower rates of COVID-19 cases, emergency department visits, and hospital admissions, particularly during the Delta variant period.
  • The effectiveness of vaccines in reducing health impacts was stronger during the Delta wave, while the benefits diminished during the Omicron period, highlighting the need for promoting pediatric vaccinations despite potential limitations against evolving virus variants.
View Article and Find Full Text PDF

Vaccination with JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic) to prevent monkeypox commenced shortly after confirmation of the first monkeypox case in the current outbreak in the United States on May 17, 2022 (1). To date, more than 27,000 cases have been reported across all 50 states, the District of Columbia (DC), and Puerto Rico.* JYNNEOS vaccine is licensed by the Food and Drug Administration (FDA) as a 0.

View Article and Find Full Text PDF